Pioneers in reproductive medicine to recruit patients for clinical trial of new method of testing embryos for chromosome abnormalities

Guidelines focus on lifestyle and behavioral management, pharmacologic approaches, and strategies for avoiding and treating diabetes-related complications

A new study shows that inhaled insulin is successful to treat Type 1 diabetes.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued a narrated scientific white paper titled: “The critical importance of selectivity when developing antibody therapies for Alzheimer’s disease.”

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).

Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's New Drug Application (NDA) for ALKS 5461.

The U.S. Food and Drug Administration permitted marketing of two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands).

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

New Assays empower Clinicians to more quickly make the right diagnosis at the point-of-care and prescribe the right treatment

Reducing prescription drug prices for patients while still encouraging pharmaceutical research and development is a difficult problem to solve politically, the founder of a web-based think tank said in the wake of attack ads against candidates.

The American Brain Tumor Association (ABTA), the nation's first nonprofit organization dedicated to brain tumor education and research, is now accepting Letters of Intent (LOI) for three research funding opportunities.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack.

Video and phone sessions can close the gap between academic-based medical settings where cancer patients are more likely to receive genetic counseling and other care settings where they may not, Penn Medicine News reported.

A study presented at the European Association for the Study of Diabetes found that patients are not storing their insulin at the recommended temperature ranges.

A genetic counseling group announced earlier this week its support for genetic testing of children during the adoption process.

The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative immunotherapy approach for multiple myeloma.

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.

Long-term care facilities play a critical role in caring for the needs of a growing aging population with a lengthening lifespan.

Agreement Establishes a New Stronghold in a Rapidly Expanding Fertility Market

Montefiore’s outstanding stroke care has been recognized by an Advanced Comprehensive Stroke Center designation, meaning that the highest standards of lifesaving stroke care are close to home for millions of New Yorkers.